Cargando…
Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits
The use of small molecule inhibitors in acute myeloid leukaemia (AML) has become ubiquitous with the US Food and Drug Administration approval of multiple agents between 2017 and 2018. Despite the promise, some of these indications are based on early efficacy data (phase I/II), and single-arm studies...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cancer Intelligence
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105340/ https://www.ncbi.nlm.nih.gov/pubmed/32256698 http://dx.doi.org/10.3332/ecancer.2020.1015 |